Trial Projects

What is a Trial Project?
1 Trial Project found
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT will also be evaluated.

Public web page: Not specified

Start date: 9th Sep 2013

End date: 3rd Jan 2022

Powered by
 (v.1.15.2)
About NFDI4Health | Partners and Funding | Credits
Copyright © 2008 - 2023 The University of Manchester and HITS gGmbH